FDA In Tug-Of-War Over Generic Cozaar/Hyzaar: Apotex And Roxane Sue Agency To Block Teva's Marketing Exclusivity
Executive Summary
FDA is engaged in a heated legal battle with Apotex and Roxane over its decision to grant Teva 180-day marketing exclusivity for generic versions of Merck's hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide)
You may also be interested in...
FDA Reluctantly Grants Teva Exclusivity For Cozaar And Hyzaar Generics
The agency says it has no choice but to award Teva exclusivity given an appeals court decision limiting forfeiture; Apotex has not decided whether it will challenge the court's ruling.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials